

## Neuroimaging

# Untangling tau imaging

Victor L. Villemagne<sup>a,b,c,\*</sup>, Nobuyuki Okamura<sup>d</sup>, Christopher C. Rowe<sup>a,c</sup>

<sup>a</sup>Department of Molecular Imaging & Therapy, Centre for PET, Austin Health, Melbourne, Australia

<sup>b</sup>The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Australia

<sup>c</sup>Department of Medicine, The University of Melbourne, Melbourne, Australia

<sup>d</sup>Department of Pharmacology, Tohoku University, Sendai, Japan


### Abstract

In vivo imaging of tau deposits is providing a better understanding of the temporal and spatial tau deposition in the brain, allowing a more comprehensive insight into the causes, diagnoses, and potentially treatment of tauopathies such as Alzheimer's disease, progressive supranuclear palsy, corticobasal syndrome, chronic traumatic encephalopathy, and some variants of frontotemporal lobar degeneration. The assessment of tau deposition in the brain over time will allow a deeper understanding of the relationship between tau and other variables such as cognition, genotype, and neurodegeneration, as well as assessing the role tau plays in ageing. Preliminary human studies suggest that tau imaging could also be used as a diagnostic, prognostic, and theranostic biomarker, as well as a surrogate marker for target engagement, patient recruitment, and efficacy monitoring for disease-specific therapeutic trials.

© 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

### Keywords:

PET; Tau imaging; Alzheimer's disease; Positron emission tomography; Tauopathies; Dementia



### Acknowledgments

We thank Professors Yukitsuda Kudo, Colin Masters, Kazuhiko Yanai, Shozo Furumoto, Drs Ryuichi Harada, Michelle Fodero-Tavoletti, William P. Blatty, Mrs Svetlana Pejoska-Bozinovski, Ms Fiona Lamb, and the Brain Research Institute for their assistance with this study. This review was supported in part by NHMRC Project Grant 1044361. VLV is supported by NHMRC Research Fellowship 1046471. The funding sources had no input into the design of this study, the analysis of data, or writing of the manuscript.

V.L.V. has received speaker honoraria from GE Healthcare, Piramal Imaging, and Avid Radiopharmaceuticals and consulting honoraria from Novartis and Lundbeck. N.O. has received research support from Clino Co. Ltd. THK compounds have been licensed to GE Healthcare. C.C.R. has received speaker honoraria from received speaker and consulting honoraria

from GE Healthcare, Piramal Imaging, Avid Radiopharmaceuticals, Navidea, and AstraZeneca.

\*Corresponding author. Tel.: +61-394963321; Fax: +61-3-9496 5663.  
E-mail address: [victorlv@unimelb.edu.au](mailto:victorlv@unimelb.edu.au)

<http://dx.doi.org/10.1016/j.dadm.2016.05.001>

2352-8729/© 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Supplementary data

Supplementary data related to this article can be found at <http://dx.doi.org/10.1016/j.dadm.2016.05.001>.

Reference mentioned in this video article can be found here.

## References

- [1] Chen-Plotkin AS, Lee VM, Trojanowski JQ. TAR DNA-binding protein 43 in neurodegenerative disease. *Nat Rev Neurol* 2010; 6:211–20.
- [2] Rabinovici GD, Miller BL. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. *CNS Drugs* 2010;24:375–98.
- [3] Seelaar H, Rohrer JD, Pijnenburg YA, Fox NC, van Swieten JC. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. *J Neurol Neurosurg Psychiatry* 2011;82:476–86.
- [4] Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. *Ann Neurol* 2004;55:306–19.
- [5] Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. *Lancet Neurol* 2008;7:129–35.
- [6] Rowe CC, Pejoska S, Mulligan RS, Jones G, Chan JG, Svensson S, et al. Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for beta-amyloid imaging in aging and dementia. *J Nucl Med* 2013;54:880–6.
- [7] Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. *Ann Neurol* 2010;68:319–29.
- [8] Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). *J Nucl Med* 2010;51:913–20.
- [9] Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. *Brain Res Brain Res Rev* 2000;33:95–130.
- [10] Maas T, Eidenmuller J, Brandt R. Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments. *J Biol Chem* 2000;275:15733–40.
- [11] Li X, Kumar Y, Zempel H, Mandelkow EM, Biernat J, Mandelkow E. Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration. *EMBO J* 2011;30:4825–37.
- [12] Hernandez F, Avila J. Tauopathies. *Cell Mol Life Sci* 2007; 64:2219–33.
- [13] Arima K. Ultrastructural characteristics of tau filaments in tauopathies: immuno-electron microscopic demonstration of tau filaments in tauopathies. *Neuropathology* 2006;26:475–83.
- [14] Zempel H, Luedtke J, Kumar Y, Biernat J, Dawson H, Mandelkow E, et al. Amyloid-beta oligomers induce synaptic damage via Tau-dependent microtubule severing by TTL6 and spastin. *EMBO J* 2013;32:2920–37.
- [15] Zempel H, Thies E, Mandelkow E, Mandelkow EM. Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. *J Neurosci* 2010;30:11938–50.
- [16] Braak H, Braak E. Evolution of neuronal changes in the course of Alzheimer's disease. *J Neural Transm Suppl* 1998;53:127–40.
- [17] Delacourte A, David JP, Sergeant N, Buee L, Wattez A, Vermersch P, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. *Neurology* 1999;52:1158–65.
- [18] Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. *Neurobiol Aging* 1997;18:351–7.
- [19] Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological Alterations in Alzheimer Disease. *Cold Spring Harb Perspect Med* 2011;1:a006189.
- [20] Guo JL, Lee VM. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. *J Biol Chem* 2011;286:15317–31.
- [21] Mohorko N, Bresjanac M. Tau Protein And Human Tauopathies: An Overview. *Zdrav Vestn* 2008;77:35–41.
- [22] Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. *Annu Rev Neurosci* 2001;24:1121–59.
- [23] McKee AC, Cantu RC, Nowinski CJ, Hedley-Whyte ET, Gavett BE, Budson AE, et al. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. *J Neuropathol Exp Neurol* 2009;68:709–35.
- [24] Masters CL, Selkoe DJ. Biochemistry of amyloid beta-protein and amyloid deposits in Alzheimer disease. *Cold Spring Harb Perspect Med* 2012;2:a006262.
- [25] Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. *Neurology* 1992;42:631–9.
- [26] Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. *Neurology* 2007; 68:1718–25.
- [27] McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. *Ann Neurol* 1999;46:860–6.
- [28] Zempel H, Mandelkow EM. Linking amyloid-beta and tau: amyloid-beta induced synaptic dysfunction via local wreckage of the neuronal cytoskeleton. *Neurodegener Dis* 2012;10:64–72.
- [29] Ittner LM, Ke YD, Gotz J. Phosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease. *J Biol Chem* 2009;284:20909–16.
- [30] Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. *Ann Neurol* 1999;45:358–68.
- [31] Villemagne VL, Fodero-Tavoletti MT, Pike KE, Cappai R, Masters CL, Rowe CC. The ART of Loss: Aβ Imaging in the Evaluation of Alzheimer's Disease and other Dementias. *Mol Neurobiol* 2008;38:1–15.
- [32] Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. *Lancet Neurol* 2013;12:207–16.
- [33] Jack CR Jr, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. *Ann Neurol* 2012;71:765–75.
- [34] Dutra JR, Cortes EP, Vonsattel JP. Update on Hippocampal Sclerosis. *Curr Neurol Neurosci Rep* 2015;15:592.
- [35] Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. *Acta Neuropathol* 2014; 128:755–66.
- [36] Villemagne VL, Furumoto S, Fodero-Tavoletti MT, Harada R, Mulligan RS, Kudo T, et al. The Challenges of Tau Imaging. *Future Neurol* 2012;7:409–21.
- [37] Villemagne VL, Okamura N. In vivo tau imaging: Obstacles and progress. *Alzheimers Dement* 2014;10:S254–64.
- [38] Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. *Lancet Neurol* 2015; 14:114–24.
- [39] Wegmann S, Jung YJ, Chinnathambi S, Mandelkow EM, Mandelkow E, Muller DJ. Human Tau isoforms assemble into ribbon-like fibrils that display polymorphic structure and stability. *J Biol Chem* 2010;285:27302–13.

- [40] Sergeant N, Bretteville A, Hamdane M, Caillet-Boudin ML, Grognet P, Bombois S, et al. Biochemistry of Tau in Alzheimer's disease and related neurological disorders. *Expert Rev Proteomics* 2008; 5:207–24.
- [41] Martin L, Latypova X, Terro F. Post-translational modifications of tau protein: implications for Alzheimer's disease. *Neurochem Int* 2011; 58:458–71.
- [42] Spillantini MG, Goedert M. Tau protein pathology in neurodegenerative diseases. *Trends Neurosci* 1998;21:428–33.
- [43] Rosen RF, Walker LC, Levine H 3rd. PIB binding in aged primate brain: enrichment of high-affinity sites in humans with Alzheimer's disease. *Neurobiol Aging* 2011;32:223–34.
- [44] Ni R, Gillberg PG, Bergfors A, Marutle A, Nordberg A. Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue. *Brain* 2013;136:2217–27.
- [45] Scaravilli T, Tolosa E, Ferrer I. Progressive supranuclear palsy and corticobasal degeneration: lumping versus splitting. *Mov Disord* 2005;20 Suppl 12:S21–8.
- [46] Khatoun S, Grundke-Iqbal I, Iqbal K. Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer disease and control brains. *FEBS Lett* 1994;351:80–4.
- [47] Mukaetova-Ladinska EB, Harrington CR, Roth M, Wischik CM. Biochemical and anatomical redistribution of tau protein in Alzheimer's disease. *Am J Pathol* 1993;143:565–78.
- [48] Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. *JAMA* 2000;283:1571–7.
- [49] Laruelle M, Slifstein M, Huang Y. Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. *Mol Imaging Biol* 2003;5:363–75.
- [50] Pike VW. PET radiotracers: crossing the blood-brain barrier and surviving metabolism. *Trends Pharmacol Sci* 2009;30:431–40.
- [51] Villemagne VL, Klunk WE, Mathis CA, Rowe CC, Brooks DJ, Hyman BT, et al. A $\beta$  Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease. *Eur J Nucl Med Mol Imaging* 2012;39:209–19.
- [52] Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. *Am J Geriatr Psychiatry* 2002;10:24–35.
- [53] Smid LM, Kepe V, Vinters HV, Bresjanac M, Toyokuni T, Satyamurthy N, et al. Postmortem 3-D Brain Hemisphere Cortical Tau and Amyloid-beta Pathology Mapping and Quantification as a Validation Method of Neuropathology Imaging. *J Alzheimers Dis* 2013;36:261–74.
- [54] Taghavi A, Nasir S, Pickhardt M, Heyny-von Haussen R, Mall G, Mandelkow E, et al. N'-benzylidene-benzohydrazides as novel and selective tau-PHF ligands. *J Alzheimers Dis* 2011;27:835–43.
- [55] Jensen JR, Cisek K, Funk KE, Naphade S, Schafer KN, Kuret J. Research towards tau imaging. *J Alzheimers Dis* 2011;26 Suppl 3:147–57.
- [56] Honson NS, Johnson RL, Huang W, Inglese J, Austin CP, Kuret J. Differentiating Alzheimer disease-associated aggregates with small molecules. *Neurobiol Dis* 2007;28:251–60.
- [57] Kemp S, Storey L, Storey J, Rickard J, Harrington C, Wischik C, inventors; Ligands for aggregated tau molecules. International patent 2010/034982 patent 2010/034982. 2010.
- [58] Ono M, Hayashi S, Matsumura K, Kimura H, Okamoto Y, Ihara M, et al. Rhodanine and thiohydantoin derivatives for detecting tau pathology in Alzheimer's brains. *ACS Chem Neurosci* 2011;2:269–75.
- [59] Watanabe H, Ono M, Kimura H, Matsumura K, Yoshimura M, Okamoto Y, et al. Synthesis and biological evaluation of novel oxindole derivatives for imaging neurofibrillary tangles in Alzheimer's disease. *Bioorg Med Chem Lett* 2012;22:5700–3.
- [60] Matsumura K, Ono M, Yoshimura M, Kimura H, Watanabe H, Okamoto Y, et al. Synthesis and biological evaluation of novel styryl benzimidazole derivatives as probes for imaging of neurofibrillary tangles in Alzheimer's disease. *Bioorg Med Chem* 2013; 21:3356–62.
- [61] Bolander A, Kieser D, Voss C, Bauer S, Schon C, Burgold S, et al. Bis(arylvinyl)pyrazines, -pyrimidines, and -pyridazines as imaging agents for tau fibrils and beta-amyloid plaques in Alzheimer's disease models. *J Med Chem* 2012;55:9170–80.
- [62] Honson NS, Jensen JR, Darby MV, Kuret J. Potent inhibition of tau fibrillization with a multivalent ligand. *Biochem Biophys Res Commun* 2007;363:229–34.
- [63] Kudo Y, Furumoto S, Okamura N, inventors; Benzoxazole derivatives. U.S. Patent 2010/0021385 patent 2010.
- [64] Szardenings AK, Zhang W, Kolb HC, Cashion DK, Chen G, Kasi D, et al., inventors; Siemens Medical Solutions USA, Inc., assignee. Imaging Agents for Detecting Neurological Disorders. US Patent 2011/0182812 A1 patent 2011/0182812 A1. 2011.
- [65] Kudo Y, Susuki M, Suemoto T, Okamura N, Shiomitsu T, Shimazu H, inventors; Quinoline derivative as diagnostic probe for disease with tau protein accumulation. U.S. Patent 7,118,730 patent 2006.
- [66] Shao XM, Carpenter GM, Desmond TJ, Sherman P, Quesada CA, Fawaz M, et al. Evaluation of [ $^{11}\text{C}$ ]N-Methyl Lansoprazole as a Radiopharmaceutical for PET Imaging of Tau Neurofibrillary Tangles. *ACS Med Chem Lett* 2012;3:936–41.
- [67] Fawaz MV, Brooks AF, Rodnick ME, Carpenter GM, Shao X, Desmond TJ, et al. High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection. *ACS Chem Neurosci* 2014;5:718–30.
- [68] Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls. *Neuron* 2013; 79:1094–108.
- [69] Hashimoto H, Kawamura K, Igarashi N, Takei M, Fujishiro T, Aihara Y, et al. Radiosynthesis, photoisomerization, biodistribution, and metabolite analysis of  $^{11}\text{C}$ -PBB3 as a clinically useful PET probe for imaging of tau pathology. *J Nucl Med* 2014;55:1532–8.
- [70] Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. *Alzheimers Dement* 2013;9:666–76.
- [71] Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. *J Alzheimers Dis* 2013;34:457–68.
- [72] Vieira M, Saraiva MJ. Transthyretin: a multifaceted protein. *Biomol Concepts* 2014;5:45–54.
- [73] Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. *Ann Neurol* 2016;79:110–9.
- [74] Okamura N, Suemoto T, Furumoto S, Suzuki M, Shimadzu H, Akatsu H, et al. Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. *J Neurosci* 2005;25:10857–62.
- [75] Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M, et al. Novel 18F-Labeled Arylquinoline Derivatives for Noninvasive Imaging of Tau Pathology in Alzheimer Disease. *J Nucl Med* 2013;54:1420–7.
- [76] Fodero-Tavoletti MT, Okamura N, Furumoto S, Mulligan RS, Connor AR, McLean CA, et al. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. *Brain* 2011;134:1089–100.
- [77] Harada R, Okamura N, Furumoto S, Tago T, Maruyama M, Higuchi M, et al. Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology. *Eur J Nucl Med Mol Imaging* 2013;40:125–32.
- [78] Fodero-Tavoletti MT, Furumoto S, Taylor L, McLean CA, Mulligan RS, Birchall I, et al. Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies. *Alzheimers Res Ther* 2014;6:11.
- [79] Villemagne VL, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Hodges J, Harada R, et al. In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. *Eur J Nucl Med Mol Imaging* 2014; 41:816–26.

- [80] Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, et al. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. *Brain* 2014; 137:1762–71.
- [81] Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. *Lancet Neurol* 2013;12:357–67.
- [82] Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. *Science* 2007;316:750–4.
- [83] Giacobini E, Becker RE. One hundred years after the discovery of Alzheimer's disease. A turning point for therapy? *J Alzheimers Dis* 2007; 12:37–52.
- [84] Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, Bruce J, et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. *Proc Natl Acad Sci U S A* 2005;102:227–31.
- [85] Wischik C, Staff R. Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy. *J Nutr Health Aging* 2009; 13:367–9.
- [86] Duyckaerts C, Braak H, Brion JP, Buee L, Del Tredici K, Goedert M, et al. PART is part of Alzheimer disease. *Acta Neuropathol* 2015; 129:749–56.
- [87] Jellinger KA, Alafuzoff I, Attems J, Beach TG, Cairns NJ, Crary JF, et al. PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. *Acta Neuropathol* 2015;129:757–62.